WaveMan
WaveMan · Company
RCUS · Arcus Biosciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

RCUS Arcus Biosciences (RCUS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001724521
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
136
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $131.3K priced

What the filings say about RCUS

Insiders, 180 days
-$3.3M net sold
3 sellers · 10% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$83.5K
1 notice

Arcus Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Arcus Biosciences, Inc. insiders sold a net $3.3M of stock across 136 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Azoy Alexander
Chief Accounting Officer
SELL
2026-08-24 SECtraded 2026-08-21
2,827
$84.8K
-43.7%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jun 1, 2026.
  • The trade is 7.1% of the 39,581 shares held after it.
  • No other insider sold within 30 days.
  • 136 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Azoy Alexander sold about $84.8K of RCUS under a 10b5-1 plan on Aug 21, 2026; 136 funds added in the latest 13F quarter.
Jaen Juan C.
President
SELL
2026-07-13 SECtraded 2026-07-10
19,799
$566.4K
-37.3%
Context
  • 33 earlier Form 4 trades (code P or S) here by this insider (33 sales), the last on Jul 9, 2026.
  • The trade is 2.4% of the 822,508 shares held after it.
  • No other insider sold within 30 days.
  • 136 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Jaen Juan C. sold about $566.4K of RCUS on Jul 10, 2026; 136 funds added in the latest 13F quarter.
Jaen Juan C.
President
SELL
2026-07-13 SECtraded 2026-07-10
268
$7.9K
-37.3%
Context
  • 33 earlier Form 4 trades (code P or S) here by this insider (33 sales), the last on Jul 9, 2026.
  • The trade is 0.0% of the 822,240 shares held after it.
  • No other insider sold within 30 days.
  • 136 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Jaen Juan C. sold about $7.9K of RCUS on Jul 10, 2026; 136 funds added in the latest 13F quarter.
Jaen Juan C.
President
SELL
2026-07-13 SECtraded 2026-07-09
48,502
$1.5M
-37.3%
Context
  • 32 earlier Form 4 trades (code P or S) here by this insider (32 sales), the last on Jun 24, 2026.
  • The trade is 5.8% of the 842,307 shares held after it.
  • No other insider sold within 30 days.
  • 136 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Jaen Juan C. sold about $1.5M of RCUS on Jul 9, 2026; 136 funds added in the latest 13F quarter.
Jaen Juan C.
President
SELL
2026-06-24 SEC
6,431
$190.7K
-41.3%
Context
  • 31 earlier Form 4 trades (code P or S) here by this insider (31 sales), the last on Jun 23, 2026.
  • The trade is 0.7% of the 890,809 shares held after it.
  • 1 other insider sold within 30 days.
  • 136 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President Jaen Juan C. sold about $190.7K of RCUS on Jun 24, 2026; 1 other insider sold within 30 days and 136 funds added in the latest 13F quarter.
136 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 131 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.3M over 180 days
-$84.8K over 90 days
below 74% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
136 funds bought in last quarter
more than 79% of Pharma & Biotech
Revenue
-35.3% year over year
below 74% of Pharma & Biotech
Margin
-1069.7% net margin
below 86% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
14.5% of the float short (float per yahoo 2026-10-26) · 7.6 days to cover · settled 2026-09-30
more than 72% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch RCUS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+5.8%12M
+0%+29%+59%+88%2025-102025-122026-022026-042026-062026-082026-10 2025-12-04 · Jaen Juan C. sold $2.1M2026-07-09 · Jaen Juan C. sold $1.5M2025-10-29 · Jaen Juan C. sold $976.9K2025-11-07 · Jarrett Jennifer sold $954.0K2025-11-17 · Jaen Juan C. sold $750.8K2025-12-16 · ROSEN TERRY J sold $633.4K2026-01-05 · Jaen Juan C. sold $633.2K2025-10-29 · Jaen Juan C. sold $632.2K2025-12-17 · ROSEN TERRY J sold $570.5K2026-07-10 · Jaen Juan C. sold $566.4K2026-06-23 · Jaen Juan C. sold $389.5K2025-10-28 · Jaen Juan C. sold $384.0K2026-06-22 · Jaen Juan C. sold $249.6K2025-12-16 · Jarrett Jennifer sold $245.6K2025-12-16 · Jaen Juan C. sold $245.6K2025-12-17 · Jarrett Jennifer sold $221.2K2025-12-17 · Jaen Juan C. sold $221.2K2026-05-11 · Goeltz II Robert C. sold $199.0K2026-06-24 · Jaen Juan C. sold $190.7K2025-12-16 · Tang Carolyn C. sold $167.6K2025-11-17 · Jaen Juan C. sold $162.3K2025-12-31 · Goeltz II Robert C. sold $153.2K2025-12-17 · Tang Carolyn C. sold $150.9K2025-12-16 · Goeltz II Robert C. sold $146.6K2025-12-17 · Goeltz II Robert C. sold $132.1K2025-11-26 · Goeltz II Robert C. sold $125.0K2025-12-16 · Markus Richard sold $110.5K2025-10-28 · Goeltz II Robert C. sold $100.0K2025-11-18 · Jaen Juan C. sold $99.7K2025-12-17 · Markus Richard sold $99.6K2025-12-18 · Azoy Alexander sold $96.6K2025-10-30 · Jaen Juan C. sold $87.7K2026-08-21 · Azoy Alexander sold $84.8K2026-06-01 · Azoy Alexander sold $66.0K2025-12-16 · Azoy Alexander sold $52.0K2025-11-26 · Azoy Alexander sold $49.4K2026-06-23 · Jaen Juan C. sold $47.6K2025-12-17 · Azoy Alexander sold $46.8K2026-01-05 · Jaen Juan C. sold $45.9K2025-10-29 · Jaen Juan C. sold $17.6K2026-07-10 · Jaen Juan C. sold $7.9K2026-01-05 · Jaen Juan C. sold $2.3K2026-08-21 · ALEXANDER AZOY filed to sell $83.5K2026-07-09 · Juan Jaen filed to sell $749.0K2026-06-24 · Juan Jaen filed to sell $1.4M2026-06-22 · Juan Jaen filed to sell $680.8K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns RCUS: institutional holders (13F)

13F holdings, latest reported quarter
GILEAD SCIENCES, INC.
31,424,760 sh
$968.8M
BlackRock, Inc.
16,416,249 sh
$506.1M
STATE STREET CORP
6,029,484 sh
$185.9M
WELLINGTON MANAGEMENT GROUP LLP
5,895,448 sh
$181.8M
MONTANOVA CAPITAL, LLC
4,776,423 sh
$147.3M

Congress trades in RCUS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

RCUS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
ALEXANDER AZOY
Filed 2026-08-21
$83.5K
Juan Jaen
Filed 2026-07-09
$749.0K
Juan Jaen
Filed 2026-06-24
$1.4M
Juan Jaen
Filed 2026-06-22
$680.8K

RCUS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Genomics Immunology and Healthcare ETF
$5.1M position · as of 2026-07-31
2.7%
Nomura Healthcare Fund
$11.7M position · as of 2026-06-30
1.6%
Tema Oncology ETF
$2.1M position · as of 2026-05-31
1.2%
Invesco S&P SmallCap Health Care ETF
$1.5M position · as of 2026-05-31
1.1%
Virtus Biotech Clinical Trials Etf
$368.2K position · as of 2026-07-31
0.8%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$79.8M position · as of 2026-06-30
0.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
32 registered trials, 6 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
24
Phase 1
4 active
3
Phase 2
0 active
3
Phase 3
2 active
2
Multi-phase
0 active
What changed recently
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in A
2026-10-27 · Active Not Recruiting → Completed
Phase 2
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cance
2026-10-20 · Active Not Recruiting → Completed
Phase 2
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malig
2026-10-10 · Active Not Recruiting → Completed
Phase 1
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointe
2026-09-10 · Active Not Recruiting → Completed
Phase 1
Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participa
2026-09-05 · Not Yet Recruiting → Recruiting
Phase 1
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Che
2026-09-04 · Completion moved 2026-08 → 2026-08-28
Phase 3
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr. Rosen
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$9.7M
$17.7M
$3.6M
-10%
-12%
2024
$7.3M
$4.8M
$2.8M
+47%
-5%
2023
$10.1M
$7.5M
$4.2M
+94%
-6%
2022
$9.0M
-$2.1M
$4.2M
+105%
-12%
2021
$9.5M
$14.6M
$5.9M
+301%
+18%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.3M sold by insiders over 180 days, 136 funds added last quarter, $83.5K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

RCUS financials

Revenue growth
-35.3%
XBRL, annual
Net margin
-1069.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$117.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-393.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$475.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.22x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-4.69x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-90.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-46.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-61.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$2.2B
market value at close 2026-10-26 on 2026-07-30 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-21.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$247.0M$258.0M$117.0M$112.0M
Operating income-$386.0M-$330.0M-$340.0M-$280.0M
Net income-$353.0M-$283.0M-$307.0M-$267.0M
EPS (diluted)-3.29-3.14-4.15-3.71
Operating cash flow-$482.0M-$170.0M-$306.0M$438.0M
Cash$222.0M$150.0M$127.0M$206.0M
Long-term debt$99.0M$48.0M$0n/a
SEC XBRL, fiscal years, as known on 2026-10-28

RCUS Stock Sonar score 6/7 axes

Find similar shapesCompare

RCUS ranks highest on institutional and government (79th percentile) and profitability (42nd), and lowest on insider conviction (12th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
42
Inputs
  • Return on equity-90.8% · 36 pct, sector of 545
  • Return on assets-46.0% · 47 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-61.1% · 42 pct, sector of 576
Financial health
36
Inputs
  • Debt to equity0.22x · 42 pct, sector of 352
  • Cash flow to debt-4.69x · 30 pct, sector of 371
Growth
22
Inputs
  • Revenue growth, YoY-35.3% · 26 pct, sector of 505
  • Backlog growth, YoY-51.0% · 18 pct, sector of 40
Insider conviction
12
Inputs
  • Net Form 4 buying (codes P and S), 180d-$3.2M · 23 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
79
Inputs
  • Funds adding, latest quarter136 · 79 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
31
Inputs
  • Short interest, % of float+14.5% · 26 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+13.5% · 35 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

RCUS filings, in plain words

Are Arcus Biosciences insiders buying or selling RCUS?

In the 180 days to 2026-10-28, Arcus Biosciences insiders were net sellers, a net $3.3M across purchases and sales reported on Form 4, by 3 sellers.

Are there planned insider sales of RCUS?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $83.5K of stock; the latest, by ALEXANDER AZOY, was filed 2026-08-21.

Read the full summary

In the 180 days to 2026-10-28, Arcus Biosciences insiders were net sellers of RCUS, a net $3.3M across purchases and sales reported on Form 4 by 3 sellers. 10% of the 10 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $83.5K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies